##gff-version 3
##sequence-region P58012 1 376
P58012	UniProtKB	Chain	1	376	.	.	.	ID=PRO_0000091861;Note=Forkhead box protein L2	
P58012	UniProtKB	DNA binding	54	148	.	.	.	Note=Fork-head;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00089	
P58012	UniProtKB	Compositional bias	35	43	.	.	.	Note=Poly-Gly	
P58012	UniProtKB	Compositional bias	221	234	.	.	.	Note=Poly-Ala	
P58012	UniProtKB	Compositional bias	284	292	.	.	.	Note=Poly-Pro	
P58012	UniProtKB	Compositional bias	301	304	.	.	.	Note=Poly-Ala	
P58012	UniProtKB	Modified residue	33	33	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:23186163;Dbxref=PMID:23186163	
P58012	UniProtKB	Cross-link	25	25	.	.	.	Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO)	
P58012	UniProtKB	Natural variant	58	58	.	.	.	ID=VAR_021196;Note=In BPES%3B sporadic%3B nuclear and cytoplasmic aggregation%3B impaired transactivation activity. S->L;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=PMID:18372316,PMID:18642388	
P58012	UniProtKB	Natural variant	63	63	.	.	.	ID=VAR_062545;Note=In BPES. I->T;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:16454982;Dbxref=dbSNP:rs1315073489,PMID:16454982	
P58012	UniProtKB	Natural variant	65	65	.	.	.	ID=VAR_046490;Note=In BPES. M->V;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18642388;Dbxref=PMID:18642388	
P58012	UniProtKB	Natural variant	66	66	.	.	.	ID=VAR_021197;Note=In BPES%3B nuclear and cytoplasmic aggregation%3B impaired transactivation activity. A->V;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=PMID:18372316,PMID:18642388	
P58012	UniProtKB	Natural variant	69	69	.	.	.	ID=VAR_021198;Note=In BPES%3B sporadic%3B nuclear aggregation%3B normal transactivation activity. E->K;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=dbSNP:rs387906920,PMID:18372316,PMID:18642388	
P58012	UniProtKB	Natural variant	80	80	.	.	.	ID=VAR_046491;Note=In BPES%3B nuclear and cytoplasmic aggregation%3B impaired transactivation activity. I->T;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=PMID:18372316,PMID:18642388	
P58012	UniProtKB	Natural variant	84	84	.	.	.	ID=VAR_046492;Note=In BPES%3B nuclear and cytoplasmic aggregation%3B impaired transactivation activity. I->N;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=PMID:18372316,PMID:18642388	
P58012	UniProtKB	Natural variant	84	84	.	.	.	ID=VAR_016883;Note=In BPES%3B type I. I->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12630957;Dbxref=dbSNP:rs28937884,PMID:12630957	
P58012	UniProtKB	Natural variant	85	85	.	.	.	ID=VAR_016884;Note=In BPES%3B sporadic. Missing;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11468277;Dbxref=PMID:11468277	
P58012	UniProtKB	Natural variant	90	90	.	.	.	ID=VAR_046493;Note=In BPES%3B nuclear and cytoplasmic aggregation%3B impaired transactivation activity. F->S;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=PMID:18372316,PMID:18642388	
P58012	UniProtKB	Natural variant	98	98	.	.	.	ID=VAR_046494;Note=In BPES%3B nuclear and cytoplasmic aggregation%3B impaired transactivation activity. W->G;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=PMID:18372316,PMID:18642388	
P58012	UniProtKB	Natural variant	98	98	.	.	.	ID=VAR_062546;Note=In BPES. W->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18484667;Dbxref=dbSNP:rs1057516149,PMID:18484667	
P58012	UniProtKB	Natural variant	101	101	.	.	.	ID=VAR_046495;Note=In BPES%3B nuclear aggregation%3B impaired transactivation activity. S->R;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=dbSNP:rs1057516151,PMID:18372316,PMID:18642388	
P58012	UniProtKB	Natural variant	102	102	.	.	.	ID=VAR_046496;Note=In BPES%3B nuclear and cytoplasmic aggregation%3B impaired transactivation activity. I->T;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=PMID:18372316,PMID:18642388	
P58012	UniProtKB	Natural variant	103	103	.	.	.	ID=VAR_046497;Note=In BPES%3B nuclear and cytoplasmic aggregation%3B normal transactivation activity. R->C;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=PMID:18372316,PMID:18642388	
P58012	UniProtKB	Natural variant	104	104	.	.	.	ID=VAR_021199;Note=In BPES%3B diffuse nuclear localization as wild type%3B normal transactivation activity. H->R;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:12938087,ECO:0000269|PubMed:18372316;Dbxref=dbSNP:rs1057516153,PMID:12938087,PMID:18372316	
P58012	UniProtKB	Natural variant	105	105	.	.	.	ID=VAR_021200;Note=In BPES%3B type II. N->S	
P58012	UniProtKB	Natural variant	106	106	.	.	.	ID=VAR_016885;Note=In BPES%3B sporadic%3B nuclear and cytoplasmic aggregation%3B impaired transactivation activity. L->F;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:12529855,ECO:0000269|PubMed:18372316;Dbxref=dbSNP:rs1057516156,PMID:12529855,PMID:18372316	
P58012	UniProtKB	Natural variant	106	106	.	.	.	ID=VAR_046498;Note=In BPES%3B nuclear and cytoplasmic aggregation%3B impaired transactivation activity. L->P;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18372316,ECO:0000269|PubMed:18642388;Dbxref=PMID:18372316,PMID:18642388	
P58012	UniProtKB	Natural variant	108	108	.	.	.	ID=VAR_062547;Note=In BPES%3B nuclear aggregation and cytoplasmic mislocalization%3B impaired transactivation activity. L->P;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18484667;Dbxref=PMID:18484667	
P58012	UniProtKB	Natural variant	109	109	.	.	.	ID=VAR_016886;Note=In BPES%3B type II%3B diffuse nuclear localization as wild type%3B impaired transactivation activity. N->K;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:12529855,ECO:0000269|PubMed:18372316;Dbxref=PMID:12529855,PMID:18372316	
P58012	UniProtKB	Natural variant	134	134	.	.	.	ID=VAR_062548;Note=In granulosa-cell tumors of the ovary%3B not commonly found in other tumor types. C->W;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:19516027,ECO:0000269|PubMed:19956657;Dbxref=dbSNP:rs1057519865,PMID:19516027,PMID:19956657	
P58012	UniProtKB	Natural variant	179	179	.	.	.	ID=VAR_021201;Note=A->G;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:12149404,ECO:0000269|PubMed:18484667;Dbxref=dbSNP:rs7432551,PMID:12149404,PMID:18484667	
P58012	UniProtKB	Natural variant	187	187	.	.	.	ID=VAR_015181;Note=In POF3%3B does not affect nuclear localization%3B reduces transcriptional activation of OSR2. G->D;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:12161610,ECO:0000269|PubMed:19429596;Dbxref=dbSNP:rs121908359,PMID:12161610,PMID:19429596	
P58012	UniProtKB	Natural variant	193	193	.	.	.	ID=VAR_021202;Note=In BPES%3B type II. K->R;Dbxref=dbSNP:rs1057516162	
P58012	UniProtKB	Natural variant	215	215	.	.	.	ID=VAR_021203;Note=In BPES. Y->C;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:15257268,ECO:0000269|PubMed:18484667;Dbxref=dbSNP:rs1057516168,PMID:15257268,PMID:18484667	
P58012	UniProtKB	Natural variant	217	217	.	.	.	ID=VAR_062549;Note=In BPES%3B diffuse nuclear localization%3B normal transcriptional activation. S->C;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18484667;Dbxref=PMID:18484667	
P58012	UniProtKB	Natural variant	217	217	.	.	.	ID=VAR_016887;Note=In BPES%3B diffuse nuclear localization%3B increased transactivation activity. S->F;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11468277,ECO:0000269|PubMed:12529855,ECO:0000269|PubMed:18372316;Dbxref=dbSNP:rs797044527,PMID:11468277,PMID:12529855,PMID:18372316	
P58012	UniProtKB	Natural variant	234	234	.	.	.	ID=VAR_037303;Note=In BPES%3B significant higher cytoplasmic retention compared to the wild-type protein. A->AAAAAA;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:17089161;Dbxref=PMID:17089161	
P58012	UniProtKB	Natural variant	234	234	.	.	.	ID=VAR_010782;Note=In BPES%3B type II. A->AAAAAAAAAAA;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11175783,ECO:0000269|PubMed:12400065;Dbxref=PMID:11175783,PMID:12400065	
P58012	UniProtKB	Natural variant	234	234	.	.	.	ID=VAR_025306;Note=In BPES. A->AAAAAAAAAAAA;Ontology_term=ECO:0000269;evidence=ECO:0000269|Ref.2	
P58012	UniProtKB	Natural variant	258	258	.	.	.	ID=VAR_021204;Note=In POF3. Y->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12149404;Dbxref=dbSNP:rs28937885,PMID:12149404	
P58012	UniProtKB	Natural variant	285	285	.	.	.	ID=VAR_015182;Note=P->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12161610;Dbxref=PMID:12161610	
P58012	UniProtKB	Natural variant	349	349	.	.	.	ID=VAR_078138;Note=R->G;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:27610946;Dbxref=dbSNP:rs201840174,PMID:27610946	
P58012	UniProtKB	Mutagenesis	25	25	.	.	.	Note=Results in reduced sumoylation. Loss of transcriptional repression activity. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19744555;Dbxref=PMID:19744555	
